<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hypersensitivity reactions to clopidogrel
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hypersensitivity reactions to clopidogrel
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hypersensitivity reactions to clopidogrel
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John R Cohn, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael P Savage, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            N Franklin Adkinson, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donald Cutlip, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 24, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H264013215">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          Clopidogrel
         </a>
         is a thienopyridine drug that inhibits platelet aggregation by blocking the adenosine diphosphate P2Y
         <sub>
          12
         </sub>
         receptor. The drug plays an essential therapeutic role in a variety of cardiovascular conditions including acute coronary syndromes, percutaneous coronary interventions with stents, stroke, and peripheral arterial disease [
         <a href="#rid1">
          1
         </a>
         ]. The most frequent use of clopidogrel is to prevent potentially fatal thrombosis of newly implanted coronary stents. Accordingly, hypersensitivity reactions to clopidogrel have particular importance in this setting, since the timing typically coincides with the period of heightened vulnerability for stent thrombosis. The most common hypersensitivity reactions to clopidogrel are dermatologic eruptions, although severe systemic reactions can also occur.
        </p>
        <p>
         The incidence and clinical manifestations of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         reactions are discussed here. Management options for dermatologic eruptions are also reviewed. Therapeutic use of clopidogrel in the management of atherosclerotic arterial disease is reviewed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/95.html" rel="external">
          "Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">
          "Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/94.html" rel="external">
          "Acute ST-elevation myocardial infarction: Antiplatelet therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">
          "Long-term antiplatelet therapy after coronary artery stenting in stable patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">
          "Antithrombotic therapy for elective percutaneous coronary intervention: General use"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17286097">
         <span class="h1">
          INCIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypersensitivity reactions to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         are reported in up to 6 percent of patients who receive the drug [
         <a href="#rid2">
          2-4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17286109">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several types of hypersensitivity reactions have been described in patients receiving
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         and other thienopyridines [
         <a href="#rid5">
          5
         </a>
         ]. The most common is a delayed skin rash [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H270258825">
         <span class="h2">
          Most common signs and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          Clopidogrel
         </a>
         hypersensitivity most commonly presents as an erythematous, macular, morbilliform rash, beginning on the face, chest, or abdomen (
         <a class="graphic graphic_picture graphicRef83637" href="/z/d/graphic/83637.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. It may or may not be pruritic. The rash usually spreads and becomes confluent, sometimes involving the proximal and then distal extremities. In one series, one-third of patients eventually had involvement of the entire body, including palms and soles [
         <a href="#rid7">
          7
         </a>
         ]. Other observations about dermatologic eruptions include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The median time from drug introduction to appearance of symptoms is between 5 and 10 days, with a peak incidence of onset at 6 days [
         <a href="#rid3">
          3,7,8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the largest available series, some patients had mild elevations in leukocytes, neutrophils, or platelet counts or decreases in lymphocyte counts [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The exact nature of the reaction is unclear, with biopsy data suggesting a lymphocyte-mediated reaction in many cases [
         <a href="#rid3">
          3
         </a>
         ]. This is consistent with the delayed onset that is most commonly reported.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H684933">
         <span class="h2">
          Other cutaneous reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other cutaneous reactions include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Localized areas of rash/dermatitis, either unilaterally or bilaterally with a symmetric distribution, usually involving the face, neck, trunk, axillae, palms, or soles [
         <a href="#rid3">
          3
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urticaria [
         <a href="#rid9">
          9
         </a>
         ], isolated angioedema [
         <a href="#rid10">
          10
         </a>
         ], or both
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pruritus without rash [
         <a href="#rid7">
          7,11
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute generalized exanthematous pustulosis (AGEP) [
         <a href="#rid12">
          12
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">
          "Acute generalized exanthematous pustulosis (AGEP)"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The overall severity of cutaneous reactions is variable. In a large multicenter comparison of over 19,000 patients receiving
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (ie, acetylsalicylic acid or ASA) and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         , cutaneous symptoms were considered severe enough to warrant drug discontinuation in 4 percent [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H270258802">
         <span class="h2">
          More serious types of systemic reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other more serious types of reactions have been described in patients receiving
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         . Although these are not discussed further in this review, and a lymphocyte driven model of the underlying pathophysiology makes anaphylaxis unlikely in any single given case, clinicians should be aware that the following have been associated with clopidogrel therapy in small numbers of cases:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stevens-Johnson syndrome (SJS) begins with a prodrome of malaise and fever, followed by the development of mucosal blistering and erythematous or purpuric macules and plaques on the skin [
         <a href="#rid13">
          13
         </a>
         ]. There is no validated skin test model for diagnosing drug-induced SJS or implicating a specific drug in the pathophysiology. (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic hypersensitivity syndromes, which consists of rash accompanied by fever, thrombocytopenia, and neutropenia [
         <a href="#rid2">
          2,14,15
         </a>
         ]. The liver and lungs may also be involved, and eosinophilia is variably seen. (See
         <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">
          "Drug reaction with eosinophilia and systemic symptoms (DRESS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aplastic anemia, which presents with fatigue and increasing anemia with a reduced absolute number of reticulocytes. This is accompanied by neutropenia and thrombocytopenia. Bacterial infections may be a presenting feature [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">
          "Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe and persistent leukopenia, which may be initially asymptomatic or present with symptoms of infection [
         <a href="#rid18">
          18,19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">
          "Drug-induced neutropenia and agranulocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum sickness-like reaction, which presents with rash, fever, malaise, polyarthralgias, and/or polyarthritis, beginning one to two weeks after first exposure [
         <a href="#rid20">
          20
         </a>
         ]. This is an uncommon complication of unclear pathophysiology, associated with elevated markers of inflammation, such as the erythrocyte sedimentation rate [
         <a href="#rid21">
          21-23
         </a>
         ]. Patients have been successfully managed by substitution of
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         [
         <a href="#rid21">
          21-23
         </a>
         ] and
         <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">
          ticlopidine
         </a>
         [
         <a href="#rid24">
          24
         </a>
         ], although a similar syndrome has been reported with ticlopidine use [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2078.html" rel="external">
          "Serum sickness and serum sickness-like reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anaphylaxis, which is a rapidly progressing multisystem reaction characterized by flushing, urticaria, angioedema, bronchospasm, laryngeal edema, and/or hypotension, is mentioned in the prescribing information as reported in postmarketing data, although the authors are not aware of detailed published reports (
         <a class="graphic graphic_table graphicRef58836" href="/z/d/graphic/58836.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In contrast, evidence from reports of drug-induced thrombotic microangiopathy (DITMA, also called drug-induced thrombotic thrombocytopenic purpura [TTP]) ascribed to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         is not considered strong enough to implicate a drug-induced etiology. (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)"
         </a>
         .)
        </p>
        <p>
         The remainder of this topic focuses on the pathogenesis, diagnosis, and management of the most common form of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         hypersensitivity (ie, an erythematous macular rash starting on the trunk and spreading to the extremities).
        </p>
        <p class="headingAnchor" id="H23907478">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of uncomplicated dermatologic reactions to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         is not known, and specific risk factors have not been identified. The loading dose of clopidogrel does not appear to impact the risk of hypersensitivity [
         <a href="#rid3">
          3
         </a>
         ]. The signs and symptoms are most suggestive of a T cell-mediated mechanism, but other types of reactions (such as urticaria and angioedema) indicate that several mechanisms are possible [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Allergy evaluations have been performed in a small number of studies to begin to assess the pathogenesis of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         reactions [
         <a href="#rid3">
          3,27
         </a>
         ]. In the largest study involving allergy testing, 62 patients underwent extensive allergy testing
         <strong>
          after
         </strong>
         they had been empirically treated through their clopidogrel reactions, completed therapy, and were free of the drug for at least four weeks [
         <a href="#rid3">
          3
         </a>
         ]. The testing was performed for the purpose of better defining the pathophysiology of clopidogrel reactions, but some important controls were lacking. Evaluation consisted of prick/puncture and intradermal testing (with a clopidogrel solution of 0.75 mg/mL) for immediate-type reactions, as well as delayed (24 hours) reading of intradermal tests. Delayed reading of intradermal tests is sometimes used to evaluate delayed-onset cutaneous reactions, although this testing method has not been validated. Patch testing (clopidogrel 20 percent in petrolatum alba and 30 percent in water) was undertaken for delayed reactions, with readings at 72 hours and up to seven days [
         <a href="#rid3">
          3
         </a>
         ]. Skin biopsy was obtained in some patients. Testing results were available for 42 patients. None had positive skin prick tests. Three had positive-immediate (ie, &lt;30 minutes) intradermal tests, all of whom had presented with urticaria or angioedema. Patch testing was positive in 81 percent. However, all patients were managed in the same way. Of note, this study did not evaluate nonreacting patients or nonexposed individuals as controls to determine the optimal concentration for skin testing or the incidence of sensitization without clinical disease, which are significant limitations. This study is discussed more below. (See
         <a class="local">
          '"Treating through"'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H264013267">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of the most common form of cutaneous reaction to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         is made clinically based upon suggestive signs and symptoms and appropriate time course [
         <a href="#rid2">
          2,7
         </a>
         ]. An appropriate skin examination should be performed based on the extent of the symptoms and the nature of the complaints. The most common presentation is an erythematous, macular, morbilliform rash, beginning on the face, chest, or abdomen, and appearing 5 to 10 days after the drug is initiated (
         <a class="graphic graphic_picture graphicRef83637" href="/z/d/graphic/83637.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
         Several laboratory tests may be helpful in excluding more serious forms of hypersensitivity reactions, since rash can be a feature of various types of reactions. The decision to obtain these tests should be based on the severity and clinical features of the patient's reaction:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood counts with differential to evaluate for eosinophilia or cytopenias
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver function tests, blood urea nitrogen, and serum creatinine to detect liver or renal involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis to look for renal involvement, microscopic hematuria, or urine eosinophilia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin biopsy for persistent, atypical, or severe cutaneous features
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23907639">
         <span class="h2">
          Allergy testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allergy testing is not necessary for the diagnosis of straightforward dermatologic reactions and is often not readily available. Studies that have examined allergy testing for
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         reactions are reviewed above. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2068280">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis primarily consists of reactions to other drugs. Many patients will have been recently exposed to other medications, such as
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (ASA), beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, statins, agents used in procedures (radiographic contrast), and drugs eluting from coronary stents. Each of these agents has been implicated in maculopapular rashes. Delayed rashes to radiocontrast agents generally resolve without treatment [
         <a href="#rid28">
          28,29
         </a>
         ]. When the cause of an apparent drug eruption is unclear, initial interventions include discontinuing noncritical medications or changing to different agents.
        </p>
        <p class="headingAnchor" id="H264013274">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who develop a dermatologic reaction to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         , there are three options for continuing antiplatelet therapy (other than
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         [ASA] monotherapy):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treating through without stopping
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         (see
         <a class="local">
          '"Treating through"'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stopping
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         and reintroducing it using a desensitization protocol (see
         <a class="local">
          'Desensitization'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stopping
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         and treating with a different antiplatelet agent (see
         <a class="local">
          'Alternate therapies'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         The initial step in managing
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         hypersensitivity reactions is deciding whether clopidogrel should be stopped because there are signs or symptoms of a potentially dangerous (ie, life-threatening) hypersensitivity reaction or if it can be continued using one of the first two options. Collaboration between the consulting cardiologist and allergist is encouraged to guide management decisions [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16155063">
         <span class="h2">
          Reactions that necessitate stopping clopidogrel
         </span>
         <span class="headingEndMark">
          —
         </span>
         Until more is known about the pathogenesis of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         reactions, the authors and editors of UpToDate suggest that clopidogrel be promptly discontinued and not reintroduced if any of the following signs or symptoms of a serious reaction are present:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Signs and symptoms of anaphylaxis, such as flushing, urticaria, or angioedema, accompanied by upper or lower airway compromise, bronchospasm, and/or hypotension (
         <a class="graphic graphic_figure graphicRef82831" href="/z/d/graphic/82831.html" rel="external">
          figure 1
         </a>
         ). Note that
         <strong>
          isolated
         </strong>
         urticaria and/or angioedema, without other symptoms, can represent a cutaneous reaction, and these patients have been managed with ongoing therapy. Anaphylaxis for this particular medication has not been consistently described.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Involvement of mucous membranes, as seen in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blistering skin rash, which is a feature of SJS, TEN, and other severe drug reactions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Involvement of organs other than the skin (eg, lungs, liver).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated fever unassociated with infection (suggesting drug fever).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent, severe hematologic changes, specifically eosinophilia, neutropenia, or thrombocytopenia. Note that some patients with dermatologic reactions have mild elevations in leukocytes, neutrophils, and/or platelets or mild decrements in lymphocyte counts at the onset of the skin changes, so patients' cell counts should be evaluated carefully. (See
         <a class="local">
          'Most common signs and symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H270258788">
         <span class="h2">
          Referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          Clopidogrel
         </a>
         reactions are often successfully managed by clinicians with experience using this medication (cardiologists, neurologists) [
         <a href="#rid11">
          11
         </a>
         ]. However, we suggest involving an allergy or dermatology specialist with experience in drug allergy if the patient demonstrates one or more of the signs and symptoms of a more serious type of reaction. Most desensitization procedures are carried out by allergy specialists. The opinion of an allergy specialist would also be helpful in cases of isolated urticaria and/or angioedema. If a severe form of hypersensitivity is suspected, then changing to an alternative agent is the safest option. (See
         <a class="local">
          'More serious types of systemic reactions'
         </a>
         above and
         <a class="local">
          'Reactions that necessitate stopping clopidogrel'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H270258018">
         <span class="h2">
          "Treating through"
         </span>
         <span class="headingEndMark">
          —
         </span>
         The administration of systemic glucocorticoids and antihistamines to reduce symptoms while continuing
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         therapy is referred to here as "treating through" [
         <a href="#rid3">
          3,8
         </a>
         ]. For patients with uncomplicated cutaneous reactions to clopidogrel and recently placed intracoronary stents, the authors and editors generally prefer treating through without stopping clopidogrel, rather than desensitization or changing to another therapy.
        </p>
        <p class="headingAnchor" id="H10390303">
         <span class="h3">
          Advantages
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary advantage of treating through is that antiplatelet therapy is continued without interruption. This is particularly important for patients with recently placed intracoronary stents in whom the risk for stent thrombosis is significantly increased if antiplatelet agents are stopped in the first days or weeks after stent placement [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 25 patients from the authors' center, 21 had rash attributed to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         as the primary presentation [
         <a href="#rid8">
          8
         </a>
         ]. Two had rash accompanied by urticaria or angioedema, and three had isolated urticaria. None had other signs suggestive of anaphylaxis. Subjects were mostly outpatients and received different combinations of antihistamines and glucocorticoids. The exact agents and doses were left to the discretion of the supervising clinician, and attempts to optimize the antiallergy regimen were not the focus of the protocol. Patients most commonly received a
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         six-day dose pack and some combination of first- and second-generation H1 antihistamines. If symptoms recurred, doses of glucocorticoids were increased and given for a longer period, and
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          montelukast
         </a>
         (10 mg daily) was added.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In this series, 22 patients were successfully treated and tolerated
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         , and 3 failed. Among the successfully treated patients, the mean duration of glucocorticoid treatment was 10±8 days. One patient required 30 days of glucocorticoid therapy, and 7 received additional drugs to suppress the reaction. All successfully treated patients were able to complete the target duration of prolonged dual antiplatelet therapy recommended by American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Clopidogrel was discontinued in the 3 patients who failed because of angioedema, desquamating rash, and uncontrollable pruritus. The investigators devised a medication protocol based on this experience (
         <a class="graphic graphic_table graphicRef83462" href="/z/d/graphic/83462.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a subsequent larger series, 62 patients were managed by treating through [
         <a href="#rid3">
          3
         </a>
         ]. Complete blood count and differential, platelet aggregation studies, and punch biopsy of affected skin were obtained. Presentations included generalized macular rash (49 subjects, confined to the trunk in 40), localized skin reaction, sometimes with peeling of the affected area (10 patients), and generalized urticaria or angioedema of the tongue or lips (3 patients). Subjects with urticaria and angioedema developed symptoms within one day of drug introduction, while the other reactions began after a median of five days of therapy. Two patients reported fever and arthralgia. Some patients had elevations in leukocytes, neutrophils, and/or platelets or depressed lymphocyte counts at the onset of symptoms (note that these hematologic changes are different from those described with hypersensitivity syndrome, which is characterized by thrombocytopenia and neutropenia). Eosinophilia was not observed. (See
         <a class="local">
          'More serious types of systemic reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         All patients were managed as outpatients, except one with angioedema who was treated under observation in the intensive care unit (ICU) [
         <a href="#rid3">
          3
         </a>
         ]. All were given
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         30 mg twice daily for five days, followed by a decrease of 5 mg twice daily every third day for 15 more days. In addition, patients received
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         , 25 to 50 mg every six to eight hours, as needed for pruritus. All patients finished the 20-day course of prednisone, during which 95 percent had resolution of symptoms at 5±2 days. All patients were able to complete the minimum required period of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         treatment (ie, four weeks for bare metal stents and 12 months for drug-eluting stents). Four patients restarted clopidogrel at a later date, and all had recurrences of hypersensitivity, which again responded to glucocorticoids and antihistamines. Once clopidogrel therapy was completed, allergy testing was performed on approximately two-thirds of the patients. Results were reviewed previously. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16154503">
         <span class="h2">
          Desensitization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug desensitization is a procedure which
         <strong>
          temporarily
         </strong>
         alters the immunologic reaction to a medication and results in short-term tolerance, allowing the patient to receive a continued course of the medication safely. Drug desensitization is best studied in immunoglobulin E (IgE)-mediated drug reactions, but it has been applied to other types of reactions as well [
         <a href="#rid33">
          33
         </a>
         ]. As noted above, the case for IgE-mediated immediate hypersensitivity has not been consistently demonstrated.
        </p>
        <p class="headingAnchor" id="H1531995">
         <span class="h3">
          Advantages
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary advantage of desensitization, compared with treating through, is that glucocorticoid therapy is not required. This may be important for some patients, provided they can be switched temporarily to another antiplatelet agent while desensitization is performed. Alternative antiplatelet agents are discussed below. (See
         <a class="local">
          'Protocol'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1532089">
         <span class="h3">
          Types of clopidogrel reactions that have been managed with desensitization
         </span>
         <span class="headingEndMark">
          —
         </span>
         The types of reactions that have been managed with desensitization are the same as those managed with treating through. In the largest series, 24 consecutive patients who had undergone placement of an intracoronary stent were treated with desensitization. Patients were excluded if their
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         reaction was anaphylaxis, angioedema involving the upper or lower airway, irritation or blistering of mucous membranes, or blistering skin rash. No patient had fever as part of his/her reaction. (See
         <a class="local">
          'More serious types of systemic reactions'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2067927">
         <span class="h3">
          Protocol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various desensitization protocols have been developed [
         <a href="#rid7">
          7,34-37
         </a>
         ]. In the largest series of 24 patients, the protocol used required eight to nine hours and was performed in the outpatient setting, except when the patient was currently hospitalized for other reasons (
         <a class="graphic graphic_table graphicRef83638" href="/z/d/graphic/83638.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. An oral solution of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         was prepared by finely crushing the drug into a liquid vehicle. Other smaller series have described longer and shorter protocols [
         <a href="#rid37">
          37,38
         </a>
         ]. No head-to-head comparisons of different protocols have been performed. With such small numbers, it is difficult to make strong recommendations concerning the safety of outpatient desensitization without there being availability of intensive treatment for anaphylaxis. However, as noted, well-characterized reports of anaphylaxis are not readily identified with clopidogrel challenge. In many instances outside of specialized research centers, such care can only be found in a hospital setting, such as an ICU or emergency department. With heightened risk if a patient with coronary disease needed intervention for anaphylaxis.
        </p>
        <p>
         Glucocorticoids are not required during desensitization, and no other premedications were given in the 24-patient series [
         <a href="#rid7">
          7
         </a>
         ]. Antihistamines and antileukotriene drugs were discontinued for seven days before the procedure. Beta-blockers are usually withheld for one to two days prior to desensitization, because beta-blockade can interfere with the ability of the patient to respond to
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         , were it to be required during the desensitization.
        </p>
        <p>
         In the 24-patient series,
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         was discontinued for five days before desensitization to allow the drug to wash out of the patient's body, during which time the rash usually resolved [
         <a href="#rid7">
          7
         </a>
         ]. This wash-out period was felt to be important, since patients who did not complete the wash-out period were more likely to react during the desensitization, although it is also possible that this reflected more severe hypersensitivity in those patients whose symptoms persisted.
        </p>
        <p>
         During the wash-out period, alternative antiplatelet agents are given to patients with recently placed intracoronary stents to prevent stent thrombosis. The safest alternative antiplatelet agent during this process is unclear. In the 24-patient series, subjects were given
         <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">
          ticlopidine
         </a>
         250 mg twice daily for five days [
         <a href="#rid7">
          7
         </a>
         ]. Other alternative drugs would include
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         or
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         , although there are no published reports for either of these drugs in this specific setting. (See
         <a class="local">
          'Alternate therapies'
         </a>
         below.)
        </p>
        <p>
         Once desensitization has been performed, patients are obligated to take
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         daily for as long as the drug is needed. If several doses are missed (the refractory period is not precisely defined), the patient will again theoretically be at risk for recurrence of the hypersensitivity reaction, and desensitization should be performed again.
        </p>
        <p class="headingAnchor" id="H2067858">
         <span class="h3">
          Success rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the series of 24 patients, all were successfully desensitized, although 1 patient required continued antihistamines, and 2 required repetition of the procedure [
         <a href="#rid7">
          7
         </a>
         ]. Only 4 patients had reactions (all cutaneous) during desensitization. All patients were able to continue therapy for six months, although 1 had mild intermittent symptoms that were managed with antihistamines, and 2 were noncompliant and required repeat desensitization. Thus, desensitization is a highly successful, although more complicated approach, compared with suppressing the reaction by treating through.
        </p>
        <p class="headingAnchor" id="H270258466">
         <span class="h1">
          ALTERNATE THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another approach to managing
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         hypersensitivity reaction is simply switching to a different antiplatelet agent, such as
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         ,
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         , or
         <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">
          ticlopidine
         </a>
         . The alternatives to clopidogrel for management of various cardiovascular disorders are reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">
          "Clopidogrel resistance and clopidogrel treatment failure", section on 'Use of alternative antiplatelet agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">
          "Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/95.html" rel="external">
          "Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'P2Y12 use'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/94.html" rel="external">
          "Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Patients receiving fibrinolytic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">
          "Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Problems with clopidogrel use'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H93593190">
         <span class="h2">
          Other P2Y12 inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         While
         <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">
          ticlopidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         , and
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         represent potential alternatives to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         , important caveats exist regarding their clinical use.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">
          Ticlopidine
         </a>
         was the first thienopyridine to be approved. Its clinical utility has been significantly hindered by adverse reactions. Over 20 percent of patients on ticlopidine discontinue therapy due to hypersensitivity reactions, gastrointestinal disturbances, neutropenia, or thrombocytopenia [
         <a href="#rid11">
          11
         </a>
         ]. Because hematologic abnormalities occur in &gt;2 percent of patients, complete blood counts are recommended every two weeks for the first three months of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          Prasugrel
         </a>
         is approved for use in patients with acute coronary syndromes treated with stent placement and is associated with fewer cardiovascular events compared with
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         in this setting [
         <a href="#rid39">
          39
         </a>
         ]. However, prasugrel is contraindicated with prior stroke or transient ischemic attack, age &gt;75 years, weight &lt;60 kg, or increased bleeding risk. As both prasugrel and clopidogrel are thienopyridines, some patients display cross-reactivity to the two drugs [
         <a href="#rid3">
          3,40
         </a>
         ]. (See
         <a class="local">
          'Cross-reactivity among drugs'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          Ticagrelor
         </a>
         is a reversible P2Y
         <sub>
          12
         </sub>
         inhibitor, which is a nonthienopyridine. Ticagrelor is approved for use in patients with acute coronary syndromes (with or without stent placement) or a history of myocardial infarction due to its superior efficacy in reducing cardiovascular events compared with
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         [
         <a href="#rid41">
          41
         </a>
         ]. Information about cross-reactivity with clopidogrel is limited. (See
         <a class="local">
          'Cross-reactivity among drugs'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Both
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         and
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         are more potent antiplatelet agents than
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         , and both are also associated with higher risk of bleeding [
         <a href="#rid39">
          39,42
         </a>
         ]. It is also important to note that ticagrelor and prasugrel are approved for patients with acute coronary syndromes but are not approved for patients treated with elective stent placement for stable coronary artery disease.
        </p>
        <p class="headingAnchor" id="H17286196">
         <span class="h2">
          Cross-reactivity among drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are limited studies of potential cross-reactivity between
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         and related P2Y
         <sub>
          12
         </sub>
         inhibitors [
         <a href="#rid3">
          3,40,43,44
         </a>
         ]. Briefly, evidence suggests that up to one-third of patients with reactions to clopidogrel will have similar reactions to
         <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">
          ticlopidine
         </a>
         . Less is known about cross-reactivity between clopidogrel and other drugs (
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         ,
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study of 52 patients with hypersensitivity or hematologic reactions to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         found that 27 percent of patients developed a similar (although not more severe) reaction when given
         <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">
          ticlopidine
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          Prasugrel
         </a>
         has been successfully used in patients with
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         hypersensitivity [
         <a href="#rid44">
          44-46
         </a>
         ]. A review of the literature identified 11 published case studies of patients with clopidogrel hypersensitivity who were subsequently treated with prasugrel [
         <a href="#rid47">
          47
         </a>
         ]. All had undergone coronary stenting procedures. Prasugrel was successfully used without cross-reactivity in 9 of the 11 patients (82 percent). However, other case reports described patients with clopidogrel hypersensitivity who developed either a similar rash or angioedema to prasugrel or
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         [
         <a href="#rid40">
          40,48
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other case reports described successful use of
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         as an alternative agent in patients with
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         hypersensitivity [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H93593204">
         <span class="h1">
          COMMON CLINICAL SCENARIOS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The issue of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         hypersensitivity typically arises in one of two clinical scenarios. In the first and more common scenario, clopidogrel is initiated at the time of coronary stent placement, and the patient develops a hypersensitivity reaction during the first week of therapy. In the second scenario, a patient who has a prior remote history of allergy to clopidogrel and is no longer taking the drug develops a new cardiovascular condition warranting clopidogrel therapy.
        </p>
        <p class="headingAnchor" id="H93593382">
         <span class="h2">
          Reactions soon after initiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          Clopidogrel
         </a>
         hypersensitivity is particularly problematic in patients with recently implanted coronary stents, since the risk of stent thrombosis from interruption of antiplatelet therapy is greatest during this period. Given its relative simplicity and effectiveness, we favor the treating through strategy for such patients, since this allows uninterrupted continuation of the drug (
         <a class="graphic graphic_table graphicRef83462" href="/z/d/graphic/83462.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          '"Treating through"'
         </a>
         above.)
        </p>
        <p>
         While most patients achieve a lasting response to a single short course of glucocorticoids, some patients will have a recrudescence of their rash after the glucocorticoid course is completed. In these occasional cases, referral to an allergy specialist, reinstitution of a longer course of glucocorticoids, or switching to an alternative P2Y
         <sub>
          12
         </sub>
         inhibitor would be appropriate options. (See
         <a class="local">
          'Desensitization'
         </a>
         above and
         <a class="local">
          'Alternate therapies'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H93593389">
         <span class="h2">
          Retreatment after a past reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a previous allergy to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         who are no longer on the drug may develop a cardiovascular condition where clopidogrel is again indicated. Simply reinstituting clopidogrel is not recommended, as this will typically result in a recurrent hypersensitivity reaction [
         <a href="#rid3">
          3
         </a>
         ]. Options for management are significantly impacted by the patient's clinical presentation and cardiac diagnosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients presenting with an acute coronary syndrome, particularly if coronary stenting is performed, use of one of the newer alternative P2Y
         <sub>
          12
         </sub>
         inhibitors would be the preferred approach. Not only would the likelihood of another allergic reaction be reduced, but also these agents improve cardiac outcomes in this clinical setting [
         <a href="#rid39">
          39,42
         </a>
         ]. Theoretically,
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         might be slightly advantageous over
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         , since the latter is a thienopyridine with some potential for cross-reactivity [
         <a href="#rid3">
          3,40
         </a>
         ]. Both ticagrelor and prasugrel carry a higher risk of bleeding compared with
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         . (See
         <a class="local">
          'Alternate therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with past
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         hypersensitivity who do not have an acute coronary syndrome, we suggest desensitization (
         <a class="graphic graphic_table graphicRef83638" href="/z/d/graphic/83638.html" rel="external">
          table 3
         </a>
         ). Use of
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         or
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         , with the concomitant higher risk of bleeding, would be less justifiable in this lower acuity scenario. (See
         <a class="local">
          'Desensitization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H270258678">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common form of hypersensitivity to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         presents as an erythematous macular rash starting on the trunk and spreading to the extremities, beginning approximately one week after the initiation of clopidogrel (
         <a class="graphic graphic_picture graphicRef83637" href="/z/d/graphic/83637.html" rel="external">
          picture 1
         </a>
         ). The pathogenesis is not known, although a lymphocyte-mediated response is suspected. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above and
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          Clopidogrel
         </a>
         has also been implicated in a variety of potentially life-threatening types of hypersensitivity reactions, some of which include rash. (See
         <a class="local">
          'More serious types of systemic reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         hypersensitivity is made clinically, based upon appropriate signs, symptoms, and timing. Laboratory studies are performed to exclude more serious types of reactions. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients with uncomplicated cutaneous reactions to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         , there are three options for future antiplatelet therapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treating through without stopping
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         (
         <a class="graphic graphic_table graphicRef83462" href="/z/d/graphic/83462.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          '"Treating through"'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stopping
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         and reintroducing it using a desensitization protocol (
         <a class="graphic graphic_table graphicRef83638" href="/z/d/graphic/83638.html" rel="external">
          table 3
         </a>
         ) (see
         <a class="local">
          'Desensitization'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stopping
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         and treating with a different antiplatelet agent (see
         <a class="local">
          'Alternate therapies'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with uncomplicated cutaneous reactions to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         and recently placed intracoronary stents, we suggest treating through without stopping clopidogrel, rather than desensitization (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Reactions soon after initiation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with uncomplicated cutaneous reactions to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         who require the drug for secondary prevention of stroke or other manifestations of cardiovascular disease
         <strong>
          and
         </strong>
         who are at risk for complications of glucocorticoid therapy or wish to avoid glucocorticoids for other reasons, we suggest stopping clopidogrel and reintroducing it using a desensitization protocol, rather than treating through (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with past
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         hypersensitivity who stopped the drug and then later developed an acute coronary syndrome, we suggest treatment with one of the newer alternative P2Y
         <sub>
          12
         </sub>
         inhibitors, such as
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         or
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), rather than administering clopidogrel again. Theoretically, ticagrelor might be the better choice, since prasugrel is a thienopyridine with some potential for cross-reactivity. (See
         <a class="local">
          'Retreatment after a past reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with past
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         hypersensitivity who stopped the drug and then later developed a need for clopidogrel
         <strong>
          other than
         </strong>
         an acute coronary syndrome, we suggest desensitization (
         <a class="graphic graphic_table graphicRef83638" href="/z/d/graphic/83638.html" rel="external">
          table 3
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Retreatment after a past reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Savage MP, Fischman DL. Clopidogrel Hypersensitivity: Overview of the Problem. Curr Vasc Pharmacol 2019; 17:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lokhandwala J, Best PJ, Henry Y, Berger PB. Allergic reactions to clopidogrel and cross-reactivity to other agents. Curr Allergy Asthma Rep 2011; 11:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheema AN, Mohammad A, Hong T, et al. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J Am Coll Cardiol 2011; 58:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calogiuri GF, Al-Sowaidi S, Nettis E, et al. A joint allergist/cardiologist classification for thienopyridines hypersensitivity reactions based on their symptomatic patterns and its impact on the management strategies. Int J Cardiol 2016; 222:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford MK, Cohn JR. Clopidogrel Hypersensitivity: Pathogenesis, Presentation and Diagnosis. Curr Vasc Pharmacol 2019; 17:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Tiehl KF, Price MJ, Valencia R, et al. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007; 50:2039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell KL, Cohn JR, Fischman DL, et al. Management of clopidogrel hypersensitivity without drug interruption. Am J Cardiol 2011; 107:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khambekar SK, Kovac J, Gershlick AH. Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues. Heart 2004; 90:e14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer TC, Worm M, Groneberg DA. Clopidogrel-associated angioedema. Am J Med 2003; 114:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell KL, Cohn JR, Savage MP. Clopidogrel hypersensitivity: clinical challenges and options for management. Expert Rev Clin Pharmacol 2010; 3:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellerbroek JC, Cleveland MG. Clopidogrel-associated acute generalized exanthematous pustulosis. Cutis 2011; 87:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeung YJ, Lee JY, Oh MJ, et al. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome. Allergy Asthma Immunol Res 2010; 2:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doogue MP, Begg EJ, Bridgman P. Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. Mayo Clin Proc 2005; 80:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andres E, Perrin AE, Alt M, et al. Febrile pancytopenia associated with clopidogrel. Arch Intern Med 2001; 161:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer B, Staudinger T, Lechner K. Clopidogrel and aplastic anaemia. Lancet 2001; 357:1446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trivier JM, Caron J, Mahieu M, et al. Fatal aplastic anaemia associated with clopidogrel. Lancet 2001; 357:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akcay A, Kanbay M, Agca E, et al. Neutropenia due to clopidogrel in a patient with end-stage renal disease. Ann Pharmacother 2004; 38:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy MW, Kockler DR. Clopidogrel-associated leukopenia. Ann Pharmacother 2003; 37:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips EJ, Knowles SR, Shear NH. Serum sickness-like reaction associated with clopidogrel. Br J Clin Pharmacol 2003; 56:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams MF, Maloof JA 3rd. Resolution of clopidogrel-associated polyarthritis after conversion to prasugrel. Am J Health Syst Pharm 2014; 71:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal S, Harburger J, Stallings G, et al. Clopidogrel-Induced Recurrent Polyarthritis. J Investig Med High Impact Case Rep 2013; 1:2324709613500239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanadiya MK, Singhal S, Koshal VB. Prasugrel as a safe alternative for clopidogrel-associated arthritis. J Invasive Cardiol 2011; 23:E137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan EA, Blake JW, Stamp LK. Ticlopidine as a safe alternative for clopidogrel-associated arthritis. J Rheumatol 2009; 36:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dakik HA, Salti I, Haidar R, Uthman IW. Drug points: Ticlopidine associated with acute arthritis. BMJ 2002; 324:27.
          </a>
         </li>
         <li class="breakAll">
          Prescribing information is available through the US Food and Drug Administration website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on December 04, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vigo PG, MacDowell AL, Wedner HJ. Successful desensitization with clopdogrel after a positive skin test (Abstract 44). Ann Allergy Asthma Immunol 2005; 94:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guéant-Rodriguez RM, Romano A, Barbaud A, et al. Hypersensitivity reactions to iodinated contrast media. Curr Pharm Des 2006; 12:3359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasdenteufel F, Waton J, Cordebar V, et al. Delayed hypersensitivity reactions caused by iodixanol: an assessment of cross-reactivity in 22 patients. J Allergy Clin Immunol 2011; 128:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calogiuri G, Mandurino-Mirizzi A, Parlangeli C, et al. Comparing Allergist and Cardiologist Considerations for the Optimal Management of Thienopyridines Hypersensitivity. Endocr Metab Immune Disord Drug Targets 2019; 19:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109:1930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solensky R. Drug desensitization. Immunol Allergy Clin North Am 2004; 24:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker NE, Fasano MB, Hobbs RA, Horwitz PA. Clopidogrel desensitization protocol for the treatment of thienopyridine hypersensitivity. Crit Pathw Cardiol 2007; 6:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee-Wong M, Gadhvi D, Resnick D. Clopidogrel desensitization. Ann Allergy Asthma Immunol 2006; 96:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Interv 2005; 65:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fajt M, Petrov A. Clopidogrel hypersensitivity: a novel multi-day outpatient oral desensitization regimen. Ann Pharmacother 2010; 44:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez-Lopez J, Muñoz-Cano R, Bartra J, et al. Desensitization to clopidogrel: a growing need. Allergy 2010; 65:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raccah BH, Shalit M, Danenberg HD. Allergic reaction to prasugrel and cross-reactivity with clopidogrel. Int J Cardiol 2012; 157:e48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lokhandwala JO, Best PJ, Butterfield JH, et al. Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. Circ Cardiovasc Interv 2009; 2:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Werkum JW, Braber TL, Verheggen PW, Van Der Have-Roeffel SM. Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel. Platelets 2011; 22:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peppard SR, Held-Godgluck BM, Beddingfield R. Use of prasugrel in a patient with clopidogrel hypersensitivity. Ann Pharmacother 2011; 45:e54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felix-Getzik E, Sylvia LM. Prasugrel use in a patient allergic to clopidogrel: effect of a drug shortage on selection of dual antiplatelet therapy. Am J Health Syst Pharm 2013; 70:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siu H, Kaliyadan A, Fischman DL, et al. Use of prasugrel in the setting of clopidogrel hypersensitivity: Case report and systematic review of the literature. Platelets 2016; 27:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chin N, Rangamuwa K, Mariasoosai R, et al. Oral antiplatelet agent hypersensitivity and cross-reactivity managed by successful desensitisation. Asia Pac Allergy 2015; 5:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manchette AM, Drucker AG, Januzzi JL Jr. Acute coronary syndrome antiplatelet alternatives in clopidogrel allergy. Pharmacotherapy 2014; 34:e152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris JR, Coons JC. Ticagrelor Use in a Patient With a Documented Clopidogrel Hypersensitivity. Ann Pharmacother 2014; 48:1230.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 82798 Version 14.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30124153" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clopidogrel Hypersensitivity: Overview of the Problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20941557" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Allergic reactions to clopidogrel and cross-reactivity to other agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21939827" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8918275" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27505343" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A joint allergist/cardiologist classification for thienopyridines hypersensitivity reactions based on their symptomatic patterns and its impact on the management strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30381080" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clopidogrel Hypersensitivity: Pathogenesis, Presentation and Diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18021870" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clopidogrel desensitization after drug-eluting stent placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21247516" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Management of clopidogrel hypersensitivity without drug interruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14966075" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12543298" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clopidogrel-associated angioedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22111683" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clopidogrel hypersensitivity: clinical challenges and options for management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21644491" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clopidogrel-associated acute generalized exanthematous pustulosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20358026" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16212151" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11146710" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Febrile pancytopenia associated with clopidogrel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11360950" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clopidogrel and aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11273071" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Fatal aplastic anaemia associated with clopidogrel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15292496" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Neutropenia due to clopidogrel in a patient with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12549951" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clopidogrel-associated leukopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14651737" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Serum sickness-like reaction associated with clopidogrel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24939499" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Resolution of clopidogrel-associated polyarthritis after conversion to prasugrel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26425581" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clopidogrel-Induced Recurrent Polyarthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21646658" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prasugrel as a safe alternative for clopidogrel-associated arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19342727" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ticlopidine as a safe alternative for clopidogrel-associated arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11777802" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Drug points: Ticlopidine associated with acute arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11777802" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Drug points: Ticlopidine associated with acute arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Successful desensitization with clopdogrel after a positive skin test (Abstract 44)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17017930" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hypersensitivity reactions to iodinated contrast media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21782229" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Delayed hypersensitivity reactions caused by iodixanol: an assessment of cross-reactivity in 22 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30215337" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Comparing Allergist and Cardiologist Considerations for the Optimal Management of Thienopyridines Hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15078797" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Stent thrombosis after successful sirolimus-eluting stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15870416" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15242719" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Drug desensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667884" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clopidogrel desensitization protocol for the treatment of thienopyridine hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16729795" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clopidogrel desensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15973671" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clopidogrel (Plavix) desensitization: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20009004" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clopidogrel hypersensitivity: a novel multi-day outpatient oral desensitization regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796212" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Desensitization to clopidogrel: a growing need.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17982182" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Prasugrel versus clopidogrel in patients with acute coronary syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21996411" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Allergic reaction to prasugrel and cross-reactivity with clopidogrel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25773268" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Long-term use of ticagrelor in patients with prior myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19717846" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20031738" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20873964" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21896923" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Use of prasugrel in a patient with clopidogrel hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23456404" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prasugrel use in a patient allergic to clopidogrel: effect of a drug shortage on selection of dual antiplatelet therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27494368" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Use of prasugrel in the setting of clopidogrel hypersensitivity: Case report and systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25653921" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Oral antiplatelet agent hypersensitivity and cross-reactivity managed by successful desensitisation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24898185" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Acute coronary syndrome antiplatelet alternatives in clopidogrel allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24958490" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Ticagrelor Use in a Patient With a Documented Clopidogrel Hypersensitivity.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
